These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23911948)

  • 1. Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
    Paulsen JS; Smith MM; Long JD;
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1233-9. PubMed ID: 23911948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everyday cognition in prodromal Huntington disease.
    Williams JK; Kim JI; Downing N; Farias S; Harrington DL; Long JD; Mills JA; Paulsen JS;
    Neuropsychology; 2015 Mar; 29(2):255-67. PubMed ID: 25000321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden.
    Musso M; Westervelt HJ; Long JD; Morgan E; Woods SP; Smith MM; Lu W; Paulsen JS;
    J Int Neuropsychol Soc; 2015 Jan; 21(1):8-21. PubMed ID: 26304055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparing for preventive clinical trials: the Predict-HD study.
    Paulsen JS; Hayden M; Stout JC; Langbehn DR; Aylward E; Ross CA; Guttman M; Nance M; Kieburtz K; Oakes D; Shoulson I; Kayson E; Johnson S; Penziner E;
    Arch Neurol; 2006 Jun; 63(6):883-90. PubMed ID: 16769871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive domains that predict time to diagnosis in prodromal Huntington disease.
    Harrington DL; Smith MM; Zhang Y; Carlozzi NE; Paulsen JS;
    J Neurol Neurosurg Psychiatry; 2012 Jun; 83(6):612-9. PubMed ID: 22451099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological markers of cognition in prodromal Huntington's disease: a review.
    Papp KV; Kaplan RF; Snyder PJ
    Brain Cogn; 2011 Nov; 77(2):280-91. PubMed ID: 21889251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.
    Downing NR; Kim JI; Williams JK; Long JD; Mills JA; Paulsen JS;
    Eur J Hum Genet; 2014 Aug; 22(8):958-63. PubMed ID: 24327189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive signs in prodromal Huntington disease.
    Stout JC; Paulsen JS; Queller S; Solomon AC; Whitlock KB; Campbell JC; Carlozzi N; Duff K; Beglinger LJ; Langbehn DR; Johnson SA; Biglan KM; Aylward EH
    Neuropsychology; 2011 Jan; 25(1):1-14. PubMed ID: 20919768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive and behavioral changes in Huntington disease before diagnosis.
    Paulsen JS; Miller AC; Hayes T; Shaw E
    Handb Clin Neurol; 2017; 144():69-91. PubMed ID: 28947127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Movement sequencing in Huntington disease.
    Georgiou-Karistianis N; Long JD; Lourens SG; Stout JC; Mills JA; Paulsen JS;
    World J Biol Psychiatry; 2014 Aug; 15(6):459-71. PubMed ID: 24678867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.
    Epping EA; Mills JA; Beglinger LJ; Fiedorowicz JG; Craufurd D; Smith MM; Groves M; Bijanki KR; Downing N; Williams JK; Long JD; Paulsen JS;
    J Psychiatr Res; 2013 Oct; 47(10):1423-31. PubMed ID: 23790259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.
    Unschuld PG; Joel SE; Pekar JJ; Reading SA; Oishi K; McEntee J; Shanahan M; Bakker A; Margolis RL; Bassett SS; Rosenblatt A; Mori S; van Zijl PC; Ross CA; Redgrave GW
    Psychiatry Res; 2012; 203(2-3):166-74. PubMed ID: 22974690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.
    Misiura MB; Lourens S; Calhoun VD; Long J; Bockholt J; Johnson H; Zhang Y; Paulsen JS; Turner JA; Liu J; Kara B; Fall E;
    J Int Neuropsychol Soc; 2017 Feb; 23(2):159-170. PubMed ID: 28205498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive reserve and brain reserve in prodromal Huntington's disease.
    Bonner-Jackson A; Long JD; Westervelt H; Tremont G; Aylward E; Paulsen JS;
    J Int Neuropsychol Soc; 2013 Aug; 19(7):739-50. PubMed ID: 23702309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.